share_log

Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Benzinga ·  May 1, 2023 07:37
Soligenix Enters into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment